Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The state agency warns that the snails were found to have a "low-level presence" of rat lungworm. They note that likelihood ...

BulletinHealthcare, a leading provider of news briefings for healthcare providers, announced today the launch of its latest publication, Respiratory Report: Pulmonary and Critical Care News Briefing, ...

The aim of this study was to characterise neutrophil subsets in bronchial lavage (BL) of obstructive airway disease participants (asthma, chronic obstructive pulmonary disease ... subtype categorised ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Navega Therapeutics, a biotechnology company developing epigenetic gene therapies, today announced the receipt of a $4M Translational Science grant from CIRM for the relief of neuropathic pain.

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price ...

Weber said it is the right time to appoint a successor, given the company's "competitive growth outlook, new product launches expected from the second half of 2026 onwards, and the anticipated ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...

A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of ...